Clinical Research Directory

Inclusion Criteria: * Age \> 18 * Patient starting anticancer immunotherapy treatment(immune checkpoint inhibitors like anti-PD-1, anti-PD-L1, anti-CTLA4, anti-Lag-3, anti-Tim-3, anti-TIGIT or other new anticancer immunotherapy) in monotherapy or associatied with other anticancer molecules. * Patient who had already received immunotherapy can be eligible to IMMUCARE-BASE provided that the last immunotherapy treatment had been administered \> 6 months ago. * Patient who received written information about IMMUCARE-BASE. * Patient receiving immunotherapy as a part of a clinical trial can be eligible to IMMUCARE-BASE according to the indications given by the promoter of this trial. * Patient in a clinical trial which includes a combination of therapy with one of the drugs administered in a blind manner vs placebo, can be eligible to IMMUCARE-BASE provided that (i) the treatment administered in a blind manner is not the immunotherapy and (ii) the clinical trial allows concomitant participation of a patient in another non-interventional study. * A Patient that has been already included in IMMUCARE-BASE and who terminates the study because of a change of treatment, can be included again in IMMUCARE-BASE if he/she agrees and provided that (i) is the new treatment includes immunotherapy (alone or in association with other anticancer molecules) and (iii) the new immunotherapy treatment is administered after 6 months from the last administration of the previous immunotherapy. Inclusion criteria specific to the biological collection: -Signature of the informed consent. Exclusion Criteria: * Patient who had received immunotherapy within 6 months before entering in IMMUCARE-BASE * Minor patient * Pregnant women * Patient under juridical protection * Patient refusal to participate. Exclusion criteria for the biological collection: * Weight ≤ 50kg * Haemoglobin \< 90g/L at the time of the inclusion * Patient participating in clinical trials where blood samples are taken for ancillary studies.